“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

Robert Besthof Biography and Net Worth

Insider of NRx Pharmaceuticals

Mr. Bestof is a global biopharmaceutical executive with a 25+ year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases area, including small as well as billion-dollar brands in Ophthalmology, Neuroscience, Pain, and Pulmonary Vascular Disease. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Band and for various consulting firms. He holds a B.A. from Case Western Reserve University and a master’s in international management from the Thunderbird School of Global Management.

How do I contact Robert Besthof?: The corporate mailing address for Mr. Besthof and other NRx Pharmaceuticals executives is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. NRx Pharmaceuticals can also be reached via phone at (484) 254-6134 and via email at [email protected]. Learn More on Robert Besthof's contact information.
Has Robert Besthof been buying or selling shares of NRx Pharmaceuticals?: Robert Besthof has not been actively trading shares of NRx Pharmaceuticals during the last quarter. Most recently, Robert Besthof sold 400 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $1,176.00, for a transaction totalling $470,400.00. Learn More on Robert Besthof's trading history.
Who are NRx Pharmaceuticals' active insiders?: NRx Pharmaceuticals' insider roster includes Robert Besthof (Insider), and Alessandra Daigneault (General Counsel). Learn More on NRx Pharmaceuticals' active insiders.
Are insiders buying or selling shares of NRx Pharmaceuticals?: In the last year, NRx Pharmaceuticals insiders bought shares 2 times. They purchased a total of 23,500 shares worth more than $75,200.00. The most recent insider tranaction occured on August, 30th when Director Aaron Gorovitz bought 3,500 shares worth more than $11,200.00. Insiders at NRx Pharmaceuticals own 21.1% of the company. Learn More about insider trades at NRx Pharmaceuticals.
Information on this page was last updated on 8/30/2023.

Robert Besthof Insider Trading History at NRx Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/15/2021	Sell	400	$1,176.00	$470,400.00

Robert Besthof Buying and Selling Activity at NRx Pharmaceuticals

NRx Pharmaceuticals Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

Today's Range

Now: $3.14

$3.01

$3.14

50 Day Range

MA: $33.06

$3.00

$70.06

2 Week Range

Now: $3.14

$2.21

$12.00

Volume

102,030 shs

Average Volume

178,094 shs

Market Capitalization

$31.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02